Printer Friendly

MEI Pharm Inc buys exclusive worldwide rights to the investigational drug candidate PWT143.

M2 PHARMA-September 11, 2013-MEI Pharm Inc buys exclusive worldwide rights to the investigational drug candidate PWT143(C)2013 M2 COMMUNICATIONS

Oncology company MEI Pharma Inc (NasdaqCM:MEIP) reported on Tuesday that it has purchased the exclusive worldwide rights to the investigational drug candidate PWT143 for an undisclosed upfront payment, with no future milestone or royalty obligations.

MEI Pharma Inc has acquired the exclusive worldwide rights to PWT143 from Pathway Therapeutics Inc, a privately held pharmaceutical company.

In pre-clinical studies, PWT143 has been found to be a potent and highly selective oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that has been shown to play a critical role in the proliferation and survival of hematologic cancer cells, added MEI Pharma Inc.

Following the purchase, MEI Pharma plans to file an Investigational New Drug (IND) application for PWT143 by the end of 2014.

This acquisition expands MEI Pharma Inc's pipeline of drug candidates, also stepping its footprints in hematologic cancers.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 11, 2013
Words:171
Previous Article:WebMD Health launches new iPhone application.
Next Article:Pluristem Therapeutics Inc awarded key US patent to treat PAD with placental cells.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters